Orgenesis Inc Cash Flow Conversion Efficiency
Orgenesis Inc cash flow conversion efficiency. Based on the latest financial reports, Orgenesis Inc (ORGS) has a cash flow conversion efficiency ratio of 0.193x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.63 Million) by net assets ($-23.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Orgenesis Inc (2009–2023)
Cash flow conversion efficiency of Orgenesis Inc from 2009 to 2023. This chart illustrates how Orgenesis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Orgenesis Inc for real-time trading data and today's change.
Orgenesis Inc Cash Flow Conversion Ratio Explained
Orgenesis Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Orgenesis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orgenesis Inc ranked by their cash flow conversion efficiency. Also see market value of Orgenesis Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trainline Plc
LSE:TRN
|
0.441x |
|
RONSHINE CH.HLD.HD-00001
F:1R7
|
N/A |
|
Fanhua Inc
F:4CIA
|
0.021x |
|
Alice QUEEN Ltd
AU:AQX
|
5.144x |
|
EAM Solar ASA
OL:EAM
|
-0.355x |
|
City Chic Collective Ltd
AU:CCX
|
0.048x |
|
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
NASDAQ:CUPR
|
-0.738x |
|
Zenta Group Company Limited
NASDAQ:ZTG
|
N/A |
Annual Cash Flow Conversion Efficiency for Orgenesis Inc (2009–2023)
The table below shows the annual cash flow conversion efficiency of Orgenesis Inc from 2009 to 2023. Review Orgenesis Inc (ORGS) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-20.98 Million | $-14.84 Million | 0.707x | +268.16% |
| 2022-12-31 | $59.27 Million | $-24.92 Million | -0.420x | +39.54% |
| 2021-12-31 | $38.63 Million | $-26.87 Million | -0.695x | +53.02% |
| 2020-12-31 | $52.73 Million | $-78.05 Million | -1.480x | +31.95% |
| 2019-12-31 | $6.08 Million | $-13.22 Million | -2.175x | -382.15% |
| 2018-12-31 | $28.65 Million | $-12.92 Million | -0.451x | +17.59% |
| 2018-11-30 | $28.65 Million | $-15.68 Million | -0.547x | -101.69% |
| 2017-12-31 | $14.12 Million | $-3.83 Million | -0.271x | +24.11% |
| 2016-12-31 | $10.58 Million | $-3.78 Million | -0.358x | -185.11% |
| 2015-12-31 | $-6.44 Million | $-2.71 Million | 0.420x | -12.41% |
| 2014-12-31 | $-2.98 Million | $-1.43 Million | 0.480x | -50.94% |
| 2013-12-31 | $-2.03 Million | $-1.99 Million | 0.978x | -73.91% |
| 2012-12-31 | $-280.56K | $-1.05 Million | 3.748x | +163859.98% |
| 2011-12-31 | $-82.67K | $-189.00 | 0.002x | -99.84% |
| 2010-12-31 | $-10.32K | $-14.96K | 1.449x | +258.94% |
| 2009-12-31 | $25.85K | $-23.58K | -0.912x | -- |
About Orgenesis Inc
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more